French Medtechs Blast 'Double Whammy' Of Price Cuts, New-Product Stalemate
Executive Summary
Eric Le Roy, chief executive of the French medical technology industry association SNITEM, is angry about the national reimbursement authority's failure to get to grips with staffing shortages holding up price-setting for new technologies, and its current preoccupation with medtech pricing cuts. "Enough is enough," he said in an interview.
You may also be interested in...
French Medtechs Demand Attention To Ongoing Reimbursement Delays
French medtech manufacturers are expecting positive results from recent ministerial efforts to make the national health-care products reimbursement agency, the CEPS, speed up its current slow handling of applications for products and services to enter commercial use in France's public-health system.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.